S&P 500   3,901.36 (+0.01%)
DOW   31,261.90 (+0.03%)
QQQ   288.68 (-0.31%)
AAPL   137.59 (+0.17%)
MSFT   252.56 (-0.23%)
FB   193.54 (+1.18%)
GOOGL   2,178.16 (-1.34%)
AMZN   2,151.82 (+0.25%)
TSLA   663.90 (-6.42%)
NVDA   166.94 (-2.51%)
BABA   86.79 (-1.03%)
NIO   16.44 (-1.32%)
AMD   93.50 (-3.28%)
CGC   5.52 (-5.96%)
MU   68.90 (-0.72%)
T   20.40 (+0.94%)
GE   75.25 (-0.65%)
F   12.50 (-2.72%)
DIS   102.42 (-0.70%)
AMC   12.03 (-8.03%)
PFE   52.47 (+3.59%)
PYPL   80.54 (-0.91%)
NFLX   186.35 (+1.56%)
S&P 500   3,901.36 (+0.01%)
DOW   31,261.90 (+0.03%)
QQQ   288.68 (-0.31%)
AAPL   137.59 (+0.17%)
MSFT   252.56 (-0.23%)
FB   193.54 (+1.18%)
GOOGL   2,178.16 (-1.34%)
AMZN   2,151.82 (+0.25%)
TSLA   663.90 (-6.42%)
NVDA   166.94 (-2.51%)
BABA   86.79 (-1.03%)
NIO   16.44 (-1.32%)
AMD   93.50 (-3.28%)
CGC   5.52 (-5.96%)
MU   68.90 (-0.72%)
T   20.40 (+0.94%)
GE   75.25 (-0.65%)
F   12.50 (-2.72%)
DIS   102.42 (-0.70%)
AMC   12.03 (-8.03%)
PFE   52.47 (+3.59%)
PYPL   80.54 (-0.91%)
NFLX   186.35 (+1.56%)
S&P 500   3,901.36 (+0.01%)
DOW   31,261.90 (+0.03%)
QQQ   288.68 (-0.31%)
AAPL   137.59 (+0.17%)
MSFT   252.56 (-0.23%)
FB   193.54 (+1.18%)
GOOGL   2,178.16 (-1.34%)
AMZN   2,151.82 (+0.25%)
TSLA   663.90 (-6.42%)
NVDA   166.94 (-2.51%)
BABA   86.79 (-1.03%)
NIO   16.44 (-1.32%)
AMD   93.50 (-3.28%)
CGC   5.52 (-5.96%)
MU   68.90 (-0.72%)
T   20.40 (+0.94%)
GE   75.25 (-0.65%)
F   12.50 (-2.72%)
DIS   102.42 (-0.70%)
AMC   12.03 (-8.03%)
PFE   52.47 (+3.59%)
PYPL   80.54 (-0.91%)
NFLX   186.35 (+1.56%)
S&P 500   3,901.36 (+0.01%)
DOW   31,261.90 (+0.03%)
QQQ   288.68 (-0.31%)
AAPL   137.59 (+0.17%)
MSFT   252.56 (-0.23%)
FB   193.54 (+1.18%)
GOOGL   2,178.16 (-1.34%)
AMZN   2,151.82 (+0.25%)
TSLA   663.90 (-6.42%)
NVDA   166.94 (-2.51%)
BABA   86.79 (-1.03%)
NIO   16.44 (-1.32%)
AMD   93.50 (-3.28%)
CGC   5.52 (-5.96%)
MU   68.90 (-0.72%)
T   20.40 (+0.94%)
GE   75.25 (-0.65%)
F   12.50 (-2.72%)
DIS   102.42 (-0.70%)
AMC   12.03 (-8.03%)
PFE   52.47 (+3.59%)
PYPL   80.54 (-0.91%)
NFLX   186.35 (+1.56%)
NASDAQ:PLXP

PLx Pharma (PLXP) Stock Forecast, Price & News

$2.87
-0.10 (-3.37%)
(As of 05/20/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.79
$3.02
50-Day Range
$2.03
$4.55
52-Week Range
$1.92
$21.50
Volume
119,525 shs
Average Volume
242,119 shs
Market Capitalization
$79.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
4.33
30 days | 90 days | 365 days | Advanced Chart
Receive PLXP News and Ratings via Email

Sign-up to receive the latest news and ratings for PLx Pharma and its competitors with MarketBeat's FREE daily newsletter.

PLx Pharma logo

About PLx Pharma

PLx Pharma Inc. operates as a commercial-stage drug delivery platform technology company in the United States. The company's lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associated with pain and inflammation, including other aspirin and non-steroidal anti-inflammatory drug products; and Vazalore 81 mg liquid-filled aspirin capsules. Its product pipeline also includes PL1200 Ibuprofen 200 mg; and PL1100 Ibuprofen 400 mg, which are in Phase I clinical stage for pain, inflammation, and fever. The company sells its products through drugstores, mass merchandisers, grocery stores, and e-commerce channels. PLx Pharma Inc. was incorporated in 2002 and is headquartered in Sparta, New Jersey.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PLXP
Employees
16
Year Founded
N/A

Sales & Book Value

Annual Sales
$8.21 million
Book Value
$0.94 per share

Profitability

Net Income
$-46.13 million
Pretax Margin
-440.87%

Debt

Price-To-Earnings

Miscellaneous

Free Float
25,540,000
Market Cap
$79.04 million
Optionable
Not Optionable

Company Calendar

Last Earnings
3/11/2022
Today
5/20/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.10 out of 5 stars

Medical Sector

479th out of 1,420 stocks

Pharmaceutical Preparations Industry

212th out of 679 stocks

Analyst Opinion: 3.5Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -













PLx Pharma (NASDAQ:PLXP) Frequently Asked Questions

Is PLx Pharma a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PLx Pharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PLx Pharma stock.
View analyst ratings for PLx Pharma
or view top-rated stocks.

When is PLx Pharma's next earnings date?

PLx Pharma is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for PLx Pharma
.

How were PLx Pharma's earnings last quarter?

PLx Pharma Inc. (NASDAQ:PLXP) issued its quarterly earnings data on Friday, March, 11th. The biotechnology company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.69) by $0.04. The biotechnology company had revenue of $1.59 million for the quarter, compared to analyst estimates of $2.05 million. During the same period in the prior year, the business posted ($0.38) earnings per share.
View PLx Pharma's earnings history
.

What price target have analysts set for PLXP?

4 Wall Street analysts have issued 12-month price objectives for PLx Pharma's shares. Their forecasts range from $12.00 to $29.00. On average, they anticipate PLx Pharma's stock price to reach $21.00 in the next twelve months. This suggests a possible upside of 631.7% from the stock's current price.
View analysts' price targets for PLx Pharma
or view top-rated stocks among Wall Street analysts.

Who are PLx Pharma's key executives?
PLx Pharma's management team includes the following people:
  • Mr. Michael J. Valentino, Exec. Chairman (Age 68, Pay $393.75k) (LinkedIn Profile)
  • Ms. Natasha Giordano, CEO, Pres & Director (Age 62, Pay $884.88k)
  • Ms. Rita M. O'Connor CPA, CPA, CFO and Head of Manufacturing & Supply Chain (Age 54, Pay $623.23k)
  • Mr. Ronald R. Zimmerman, Founder & Sr. Advisor (Age 69)
  • Mr. Tom Long, VP of Manufacturing & Technical Operations
  • Ms. Janet M. Barth, VP of Investor Relations & Corp. Communications
  • Ms. Joanne Cotignola, VP of Marketing
  • Ms. Nicole Godino, National Sales Director
  • Mr. Patrick M. Lonergan, Member of Chief Exec. Officer Advisory Group (Age 87)
  • Mr. Charles Edmund Sheedy C.F.A., CFA, Member of Chief Exec. Officer Advisory Group (Age 75)
What other stocks do shareholders of PLx Pharma own?
When did PLx Pharma IPO?

(PLXP) raised $68 million in an IPO on Thursday, February 4th 2016. The company issued 3,800,000 shares at a price of $17.00-$19.00 per share. Raymond James served as the underwriter for the IPO and Maxim Group LLC and Janney Montgomery Scott were co-managers.

What is PLx Pharma's stock symbol?

PLx Pharma trades on the NASDAQ under the ticker symbol "PLXP."

Who are PLx Pharma's major shareholders?

PLx Pharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.00%), GW&K Investment Management LLC (1.55%), First Republic Investment Management Inc. (0.65%), Shay Capital LLC (0.32%), State Street Corp (0.29%) and Steward Partners Investment Advisory LLC (0.25%). Company insiders that own PLx Pharma stock include John Hadden, Michael J Valentino, Natasha Giordano and Rita M O'connor.
View institutional ownership trends for PLx Pharma
.

Which institutional investors are selling PLx Pharma stock?

PLXP stock was sold by a variety of institutional investors in the last quarter, including First Republic Investment Management Inc., Vanguard Group Inc., Simplex Trading LLC, Qube Research & Technologies Ltd, UBS Group AG, Ground Swell Capital LLC, and GW&K Investment Management LLC.
View insider buying and selling activity for PLx Pharma
or view top insider-selling stocks.

Which institutional investors are buying PLx Pharma stock?

PLXP stock was acquired by a variety of institutional investors in the last quarter, including Shay Capital LLC, MBL Wealth LLC, Shufro Rose & Co. LLC, HAP Trading LLC, Clearline Capital LP, Group One Trading L.P., Private Advisor Group LLC, and Commonwealth Equity Services LLC. Company insiders that have bought PLx Pharma stock in the last two years include John Hadden, Michael J Valentino, Natasha Giordano, and Rita M O'connor.
View insider buying and selling activity for PLx Pharma
or or view top insider-buying stocks.

How do I buy shares of PLx Pharma?

Shares of PLXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PLx Pharma's stock price today?

One share of PLXP stock can currently be purchased for approximately $2.87.

How much money does PLx Pharma make?

PLx Pharma has a market capitalization of $79.04 million and generates $8.21 million in revenue each year. The biotechnology company earns $-46.13 million in net income (profit) each year or ($2.710010) on an earnings per share basis.

How many employees does PLx Pharma have?

PLx Pharma employs 16 workers across the globe.

What is PLx Pharma's official website?

The official website for PLx Pharma is www.plxpharma.com.

How can I contact PLx Pharma?

PLx Pharma's mailing address is 9 Fishers Lane Suite E, Sparta NJ, 07871. The biotechnology company can be reached via phone at (973) 409-6541, via email at [email protected], or via fax at 713-842-3052.

This page was last updated on 5/20/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.